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Increased plasma adrenomedullin levels in hemodialysis pa- is present in approximately 10% of patients on mainte-
tients with sustained hypotension. nance hemodialysis (HD) and may be more prevalent
Background. Sustained hypotension in end-stage renal dis- in long-term HD patients [1]. Although the prevalenceease patients is characterized, despite an overactivation of the
of this complication is low, these patients require a sub-sympathetic and renin-angiotensin systems, by decreased vas-
cular resistance and a blunted vascular response to pressor stantial amount of medical and nursing care during and
stimuli. An increased production of one or more vasodilator after dialysis to control hypotensive symptoms. The
substances might play a role in the reduced vascular resistance pathophysiology of chronic hypotension in uremic pa-and response to pressor stimuli in these patients. We evaluated
tients still remains unknown, but several potential mech-the possible role of an increased production of nitric oxide and/
anisms have been implicated: the autonomic neuropathyor adrenomedullin (ADM) in the pathophysiology of chronic
hypotension in hemodialysis (HD) patients. present in uremia [2], a blunted pressor response to nor-
Methods. Three groups of hypotensive (N 5 9), normoten- epinephrine, secondary to an impaired vascular adreno-sive (N 5 10), and hypertensive (N 5 9) HD patients were
ceptor function [3–5], a decreased pressor response toincluded in the study. Plasma renin activity (PRA) and plasma
angiotensin II (Ang II) infusion associated with reducedlevels of catecholamines, ADM, nitrite/nitrate (an estimator
of nitric oxide production), tumor necrosis factor (TNF), and Ang II receptor density [6], or the increased production
interleukin-1b (IL-1b) were measured. Plasma volume and left of nitric oxide reported in uremia [7], among others.ventricular ejection fraction (LVEF) were also evaluated.
Much evidence indicates that the sympathetic nerveResults. Plasma levels of nitrite/nitrate and ADM were ele-
activity is increased in uremia. Plasma catecholaminevated in HD patients with respect to the reference values in
normal subjects. Plasma ADM levels, but not nitrite/nitrate levels have been reported to be elevated in hemodialyzed
levels, were higher in hypotensive (368.1 6 25.4 pg/mL) than patients [3–5]. Although plasma catecholamine levels in
normotensive (225 6 9.9 pg/mL) and hypertensive HD patients
uremic patients cannot be considered a reliable index(278.2 6 15.5 pg/mL, P , 0.01). When considering hypotensive
of sympathetic activity, studies using microneurographicand normotensive patients together, the mean blood pressure
inversely correlated with time on HD (r 5 20.53, P , 0.05) techniques confirmed that sympathetic overactivity is of-
and plasma ADM levels (r 5 20.78, P , 0.01). ten present in uremia [8]. Hypotensive HD patients dis-
Conclusions. Plasma ADM and nitrite/nitrate levels are in-
play even higher plasma catecholamine levels than nor-creased in HD patients, but only ADM levels were higher
motensive uremic patients [3–5], whereas the pressorin hypotensive than in normotensive and hypertensive HD
patients. The higher plasma levels of this peptide in hypotensive response to exogenous norepinephrine infusion is mark-
patients and its inverse correlation with mean arterial pressure edly blunted in these patients when compared with nor-
suggest that ADM may be involved in the pathophysiology of
motensive HD patients [3, 4], suggesting the presencechronic hypotension in HD patients.
of a postsynaptic vascular resistance to the sympathetic
stimuli. This peripheral vascular resistance to the effects
of norepinephrine has been ascribed to a reduced vascu-Chronic hypotension, defined as a systolic blood pres-
lar a-adrenoceptor number and/or function [3, 5]. Plasmasure lower than 100 mm Hg between dialysis sessions,
Ang II levels have been reported to be elevated in hypo-
tensive HD patients [6, 9], but the pressor response toKey words: vascular resistance, chronic hypotension, end-stage renal
disease, nitrite and nitrate, blood pressure. Ang II infusion in hypotensive patients is blunted with
respect to the normotensive patients [6]. Sustained hypo-Received for publication February 9, 1999
tension is therefore characterized by an activation ofand in revised form August 27, 1999
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blunted. Thus, it is tempting to speculate that an in- ments in the previous three months. The causes of ESRD
in this group were chronic glomerulonephritis (N 5 2),creased production/release of one or more vasodilator
substances, as opposed to the vascular effects of norepi- tubulointerstitial nephritis (3), polycystic kidney disease
(2), and undefined (2).nephrine or Ang II, might be implicated in the patho-
physiology of this disorder. The normotensive group included 10 normotensive
HD patients (6 men and 4 women, mean age 43.8 6 15Nitric oxide production has been reported to be in-
creased in uremia, and it has been postulated that it years, mean time on HD 7.33 6 7.5 years, mean 6 sd)
with a predialysis blood pressure #145/90 mm Hg forplays a role in the uremic bleeding diathesis and HD-
associated hypotension [7], although the possible role of the previous three months. The causes of ESRD were
chronic glomerulonephritis (N 5 2), tubulointerstitialthis molecule in sustained hypotension in uremia has not
been studied thus far. nephritis (3), polycystic kidney disease (1), nephro-
sclerosis (1), hemolytic uremic syndrome (1), and unde-Adrenomedullin (ADM) is an endogenous 52-amino
acid peptide first isolated from human pheochromocy- fined (2).
The hypertensive group included nine hemodialyzedtoma that possesses potent vasodilating properties [10].
There is increasing evidence that this peptide plays a patients (6 men and 3 women, mean age 43.9 6 13.3
years, mean time on HD 5.99 6 4.6 years, mean 6 sd).role as a paracrine/autocrine factor in the regulation of
the cardiovascular system [11]. ADM-like immunoreac- Hypertension was defined as predialysis blood pressure
levels consistently .145/90 mm Hg or the need for anti-tivity is found in numerous tissues, including adrenal
medulla, heart, brain, lungs, and kidneys, as well as in hypertensive treatment for the previous three months.
The causes of renal failure were tubulointerstitial nephri-human plasma [12]. Plasma levels of ADM have been
reported to be elevated in certain disease states in hu- tis (N 5 3), nephrosclerosis (2), chronic glomerulone-
phritis (2), lupus nephritis (1), and undefined (1).mans, including essential hypertension, chronic renal
failure, congestive heart failure, liver cirrhosis with asci- None of the patients were anephric, had evidence of
cardiac or pericardial disease, or suffered from diabetestes, and chronic obstructive pulmonary disease with hyp-
mellitus, chronic obstructive pulmonary disease, hepaticoxia [13]. It has also been recently reported that ADM
dysfunction, or other systemic diseases, such as amy-exerts a hypotensive effect in humans at the plasma levels
loidosis. All subjects had normal thyroid function. Noneobserved in some disorders of the circulation [14]. Fi-
of the hypotensive or normotensive patients receivednally, plasma ADM levels have been consistently found
antihypertensive treatment, and no patients received va-to be markedly increased in patients with chronic renal
sodilatory drugs. Antihypertensive treatment was with-failure [13, 15, 16] and in HD patients [17–20].
drawn one week before the study in hypertensive-treatedWe hypothesized that an increased production of one
patients. All patients underwent four-hour HD threeor more vasodilator substances might be the underlying
times weekly with volumetrically controlled ultrafiltra-mechanism of the reduced vascular response in sustained
tion devices and bicarbonate-containing dialysate, andhypotension in uremia, whereas the overactivation of
the medication prescribed included phosphate binders,the sympathetic and renin-angiotensin systems would
vitamins, iron supplements, and recombinant humanbe a compensatory phenomenon. Actually, an increased
erythropoietin. All subjects were studied after givingsynthesis and/or plasma levels of several endothelium-
their written informed consent, and the study was ap-derived vasodilators such as nitric oxide [7], prostacyclin
proved by the ethical committee of our institution.[21], and ADM [13–20] have been reported in uremia.
Studies were performed between 8 a.m. and 9 a.m.,This study was designed to assess the possible role of
after overnight fasting, and prior to a regularly scheduledtwo vasodilator substances, nitric oxide and ADM, in the
HD session. A cannula was inserted in an anterocubitalpathogenesis of chronic hypotension in hemodialyzed
vein for blood sampling. Subjects were placed in a supinepatients.
position for at least 45 minutes before measuring blood
pressure and blood sampling.
METHODS Blood pressure was measured three times within a
Twenty-eight patients with end-stage renal disease five-minute interval with a mercury sphygmomanometer,
(ESRD) on maintenance HD (9 hypotensive, 10 normo- and the mean of the three readings was considered. Mean
tensive, and 9 hypertensive patients) were included in arterial pressure (MAP) was calculated as the diastolic
this study. plus one third of the pulse pressure.
The hypotensive group included nine patients (4 men Blood samples were collected in prechilled tubes,
and 5 women, mean age 51.1 6 13 years, mean time on which were promptly centrifuged at 48C. Plasma cate-
HD 12.1 6 6.5 years, mean 6 sd). Chronic hypotension cholamine levels were measured by radioimmunoassay
was defined as a systolic blood pressure #100 mm Hg (RIA; IBL Laboratories, Hamburg, Germany; reference
values in our laboratory were as follows: plasma epineph-predialysis in at least 80% of blood pressure measure-
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Table 1. Demographic, hemodynamic, and laboratory values for the three groups of hemodialysis patients
Normotensive HD Hypotensive HD Hypertensive HD
Age years 43.864.8 51.164.3 43.964.7
Time on HD years 7.3362.4 12.162.2 5.9961.6
Systolic BP mm Hg 127.064.5 94.662.3b 152.862.8d
Mean BP mm Hg 90.462.5 71.062.2b 111.362.0d
Diastolic BP mm Hg 72.362.4 58.262.3b 88.861.25d
Interdialysis weight gain g 30306329 23226211 26636430
Norepinephrine pg/mL 291643.6 3606101 293.4673.1
Epinephrine pg/mL 51.869.1 50.469.8 50.8614.2
PRA ng/mL·h 0.5760.15 0.736 .0.24 0.5260.16
Nitrite/nitrate nmol/mL 109.1614.4 104.0612.7 95.4612.3
Adrenomedullin pg/mL 225.069.9 368.1625.4b 278.2615.5
Interleukin-1b pg/mL 260.1650.3 281.2626.9 105.8633.9e
Tumor necrosis factor pg/mL 58.765.0 55.565.4 55.568.6
Plasma volume mL/kg 43.762.9 50.262.8 48.963.7
LVEF % 61.361.9 61.062.6 66.363.4
Abbreviations are: HD, hemodialysis; BP, blood pressure; PRA, plasma renin activity; LVEF, left ventricular ejection fraction. Data are mean 6 sem.
a P , 0.05 and b P , 0.01 with respect to the other groups
c P , 0.05 and d P , 0.01 vs. normotensives
e P , 0.05 vs. hypotensives
rine levels 44 6 38 pg/mL, plasma norepinephrine levels values in our laboratory for TNF-a were 13.8 6 3 pg/mL
253 6 114 pg/mL). Plasma renin activity (PRA) was and for IL-1b were 44.7 6 4.4 pg/mL.
measured by RIA of Ang I generated by incubation at Plasma volume by means of the isotope dilution tech-
pH 7.4 at 378C (Incstar Corp., Stillwater, MN, USA; nique using 131I-labeled albumin and left ventricular ejec-
reference values in normal control subjects 0.28 6 0.2 tion fraction (LVEF) by isotopic ventriculography were
ng/mL · h). Plasma nitrite/nitrate levels, considered as also measured.
an estimate of nitric oxide production, were measured Data are expressed as means 6 sem. Comparisons
by a fluorometric technique, as previously described (ref- between the three groups of patients were analyzed by
erence plasma values in our laboratory 37 6 14 nmol/ using a one-way analysis of variance. Correlation coeffi-
mL) [22]. Intra-assay and interassay coefficients of varia- cients were calculated by the Spearman rank order corre-
tion were 8.4 and 14.8%, respectively. The plasma ADM lation test. Significance was defined as a P , 0.05.
concentration was measured by RIA using a commercial
kit (Phoenix Pharmaceuticals, Mountain View, CA,
RESULTSUSA), as previously described [23]. Briefly, after extrac-
Systolic, diastolic, and mean blood pressures were sig-tion of ADM on “Sep-Pak C18” cartridges (Waters As-
nificantly different in the three groups of patients, associates, Milford, MA, USA), plasma samples (2 mL)
expected (P , 0.01). No significant differences with re-were acidified with 4% acetic acid (3 mL) and applied
spect to age or sex were observed among the threetwice to cartridges preactivated with methanol, distilled
groups. Although the mean time on HD was longer inwater, and 4% acetic acid. Cartridges were then washed
hypotensive patients than in normotensive and hyperten-with distilled water and 25% ethanol, and ADM was
sive patients, the difference failed to reach statisticaleluted with 4 mL acetic acid glacial in 86% ethanol. The
significance (Table 1). No significant differences wereeluted ADM was then dried and reconstituted for RIA.
observed in interdialysis weight gain between the threeThe recovery rate for the extraction procedure was 79%,
groups.as determined by the addition for 125I-ADM to plasma.
Plasma norepinephrine levels and PRA were in-Maximum binding of the anti-ADM antibody in the RIA
creased in the whole group of HD patients with respect towas 40.6%. Intra-assay and interassay coefficients of vari-
the reference values. No significant differences in plasmaation were 12.4 and 13.6%, respectively. Dilution curves
levels of epinephrine, norepinephrine, or PRA were ob-obtained from plasma extracts paralleled the standard
served between the three groups of patients. Plasmacurve. In our laboratory, mean plasma ADM levels in
nitrite/nitrate levels were increased in hemodialyzed pa-normal control subjects were 127 6 58 pg/mL.
tients with respect to the reference values, but again, noSerum levels of tumor necrosis factor-a (TNF-a) and
significant differences were observed between the threeinterleukin-1b (IL-1b) were measured by immunoradio-
groups of patients. Plasma ADM levels were also ele-metric (Medgenix Diagnostics, Fleuris, Belgium) and en-
vated in uremic patients with respect to values in normalzyme-linked immunoabsorbent assays (DRG Instru-
ments, Marburg, Germany), respectively. Reference subjects. In addition, ADM levels were more elevated
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Fig. 1. Inverse relationship between mean arterial pressure (MAP) Fig. 2. Inverse relationship between MAP and plasma adrenomedullin
and time on hemodialysis (HD) in the group of normotensive and (ADM) in the group of normotensive and hypotensive hemodialysis
hypotensive hemodialyzed patients (r 5 20.53; P , 0.05). patients (r 5 20.78; P , 0.01).
tained hypotension in HD patients. In contrast, plasmain hypotensive HD patients than in normotensive (P ,
nitrite/nitrate levels, an estimator of nitric oxide produc-0.01) and hypertensive (P , 0.01) HD patients (Table 1).
tion, were similar in the three groups of patients, arguingSerum levels of TNF-a were similar in the three groups
against a possible role for this substance in the patho-of patients, whereas IL-1b levels were significantly lower
physiology of sustained hypotension (increased release)in hypertensive patients than in hypotensives (P , 0.05)
and hypertension (decreased production) in uremia.and in the limit of the significance versus the normoten-
In sustained hypotension in uremia, a decreased vascu-sive group (P 5 0.066). Plasma volume and LVEF were
lar resistance associated with an overactivation of thenot significantly different among the three groups of
pressor systems (sympathetic and renin-angiotensin sys-patients (Table 1).
tem) and a blunted pressor response to norepinephrineWhen considering all patients together, the MAP was
[3, 4] and Ang II [6] have been observed. In this study,inversely correlated with time on HD (r 5 20.40, P ,
plasma norepinephrine levels and PRA tended to be0.05), plasma ADM levels (r 5 20.423, P , 0.05), and
higher in hypotensive patients when compared with nor-IL-1b (r 5 20.56, P , 0.01). When considering only
motensive and hypertensive patients, in agreement withnormotensive and hypotensive patients together, MAP
previous results of our group [5, 9], as well as otherswas inversely correlated with time on HD (r 5 20.53,
[3, 6], suggesting the presence of an overactivation ofP , 0.05; Fig. 1) and plasma ADM levels (r 5 20.78,
these pressor systems in hypotensive HD patients. TheseP , 0.01; Fig. 2). Plasma nitrite/nitrate levels showed no
observations raised the possibility that an increased bio-correlation with MAP. Neither plasma nitrite/nitrate nor
synthesis and/or release of one or more vasodilator sub-plasma ADM levels showed a relationship with age, time
stances might be involved in the pathogenesis of thison HD, interdialysis weight gain, plasma norepinephrine
disorder, whereas the activation of the pressor mecha-levels, or PRA, serum levels of TNF or IL-1b, plasma
nisms would be a secondary phenomenon in order tovolume or LVEF, either when considering the whole
compensate for the excessive vasodilation.group of HD patients or only normotensive and hypoten-
Noris et al reported that nitric oxide biosynthesis wassive patients.
increased in uremia, and they postulated that this en-
hanced nitric oxide production may contribute to the
DISCUSSION platelet dysfunction observed in uremia, as well as to
Our study confirms the results of previous studies in other complications such as HD-associated hypotension
which plasma nitrite/nitrate and ADM levels are in- [7]. Our results demonstrate that plasma nitrite/nitrate
creased in HD patients. The main finding of our study is markedly increased in uremic patients, suggesting that
was that in HD patients with sustained hypotension, nitric oxide biosynthesis is in fact increased in uremia,
plasma ADM levels are further increased with respect in agreement with the previous study. However, the ob-
to normotensive and hypertensive HD patients and that servation that plasma levels of nitrite/nitrates in hypoten-
plasma ADM levels inversely correlated with MAP in sive patients were similar to those found in normotensive
HD patients. These results suggest that this vasodilator and hypertensive HD patients, and their lack of relation-
ship with MAP argues against a role for an increasedpeptide may be involved in the pathophysiology of sus-
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nitric oxide production in the pathophysiology of sus- only normotensive and hypertensive patients who were
much older than those in our study, and in contrast totained hypotension in uremic patients. Conversely,
plasma levels of nitrite/nitrate may not be representative ours, a third of them also had heart failure and 24% of
them diabetic nephropathy, two conditions associatedof local nitric oxide synthesis, and an increased nitric
oxide production in some vascular beds as a possible with increased plasma ADM levels [13, 28]. On the other
hand, our hypertensive patients showed higher, althoughmechanism of sustained hypotension cannot be com-
pletely ruled out from our study. Another word of cau- nonsignificant, plasma ADM levels than the normoten-
sive controls (23% increase). This increase was equiva-tion in interpreting these results is the fact that because
of the accumulation of nitrates in chronic renal failure, lent to the one reported by Toepfer et al in their subset
of uncomplicated hypertensive HD patients (23%) [20].the relative contribution of diet and endogenous synthe-
sis of nitric oxide in the plasma levels of nitrite/nitrates The mechanism through which plasma ADM levels
are further increased in hypotensive HD patients is un-is difficult to establish in dialysis patients.
Previous studies reported that plasma ADM levels are known. No differences in plasma volume were observed
between the three groups of patients, whereas ADMincreased in chronic renal failure [13, 15, 16] and in HD
patients [17–20]. Our results confirm that plasma ADM levels showed no relationship with plasma volume, ar-
guing against a role for hypervolemia in the increase inlevels are increased in these patients, although the cause
or causes for these increased ADM levels are still un- plasma ADM levels in the hypotensive group. LVEF
was preserved in all our patients and was similar in theknown. The main source of ADM in the circulation and
its metabolism in humans has not been conclusively three groups of patients, ruling out the possibility that
cardiac dysfunction was the cause of the increasedshown [24]. The ubiquitous production of ADM in the
cardiovascular system suggests that it may have a local plasma ADM levels in hypotensive patients. Serum lev-
els of IL-1b and TNF-a in our hypotensive patients were(autocrine and paracrine) vasodilatory role. In this sense,
it is interesting to point out that the vasodilatory effects similar to the normotensive patients, and the levels of
these cytokines showed no relationship with plasmaare more prominent in organs in which this peptide is
expressed, for example, lung, heart, kidney or adrenal ADM levels, arguing against a role for these cytokines
in the increased plasma ADM levels in hypotensive pa-gland, but not in skeletal muscle or skin [25]. Although
the levels of ADM are related to creatinine clearance tients. ADM levels have been shown to correlate with
parameters of sympathetic activity in several clinical situ-[16], the high levels of ADM in renal failure do not seem
to be simply caused by a decreased renal clearance, but ations [15, 29, 30]. As hypotensive HD patients had sym-
pathetic overactivation [3–5], it is possible that this in-also to an increased production. The regulation of ADM
is complex and influenced by circulating hormones, creased sympathetic activity may be involved in the
increased production of ADM in this subset of patients.growth factors, cytokines, IL-1, TNF, and lipopolysac-
charide [26, 27]. The recent demonstration that ADM However, plasma norepinephrine levels showed no rela-
tionship with ADM levels in our study, arguing againstlevels decrease after isolated ultrafiltration in HD pa-
tients suggests that body volume is also involved in the this possibility. The mechanism or mechanisms by which
plasma ADM levels are increased in hypotensive HDregulation of this peptide [19]. As most of these pre-
viously mentioned factors are altered in HD patients, it patients deserves further investigation, whereas the con-
firmation or not that ADM plays a role in the reducedis possible that the increased plasma ADM levels in
HD patients have a multifactorial origin related to the vascular resistance and blunted vascular resistance to
pressor stimuli in sustained hypotension in HD patientsabnormalities associated with this situation. Plasma lev-
els of ADM were higher in hypotensive HD patients needs to be explored by specific antagonists of this pep-
tide.with respect to the normotensive (63% increase) and
hypertensive patients (32% increase), suggesting that The vasodilator effects of ADM are mediated through
the interaction with specific receptors located in targetADM production was further enhanced in this subset
of patients. This observation, together with the inverse organs. It has been recently reported that the calcitonin-
receptor–like receptor can function as either a calcitonin-relationship between plasma ADM levels and MAP, sug-
gests that this vasodilator hormone can be involved in gene–related peptide (CGRP) or an ADM receptor, de-
pending on which members of the receptor-activity–the pathophysiology of sustained hypotension in uremia.
Previous studies failed to find this relationship in HD modifying proteins (RAMPs) are expressed. Thus, the
calcitonin-receptor–like receptor has two alternativepatients [17, 20]. In the first study, which failed to find
any relationship between MAP and ADM levels, the pharmacological profiles that are conferred by the acces-
sory proteins RAMP1 (producing the CGRP receptor)selection criteria were not precise and hypotensive pa-
tients did not seem to be included [17]. The study done and RAMP2 (producing the ADM receptor) [31]. The
vasodilator effects of ADM can be mediated by a directby Toepfer et al reported a positive relationship between
MAP and plasma ADM levels [20]. That study included effect on vascular smooth muscle cells to increase intra-
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3. Daul AE, Wang XL, Michel MC, Brodde OE: Arterial hypoten-cellular cAMP [32] by decreasing intracellular calcium
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